Major clinical research advances in gynecologic cancer in 2023:a tumultuous year for endometrial cancer
- Author:
Seung-Hyuk SHIM
1
;
Jung-Yun LEE
;
Yoo-Young LEE
;
Jeong-Yeol PARK
;
Yong Jae LEE
;
Se Ik KIM
;
Gwan Hee HAN
;
Eun Jung YANG
;
Joseph J NOH
;
Ga Won YIM
;
Joo-Hyuk SON
;
Nam Kyeong KIM
;
Tae-Hyun KIM
;
Tae-Wook KONG
;
Youn Jin CHOI
;
Angela CHO
;
Hyunji LIM
;
Eun Bi JANG
;
Hyun Woong CHO
;
Dong Hoon SUH
Author Information
- Publication Type:Review Article
- From:Journal of Gynecologic Oncology 2024;35(2):e66-
- CountryRepublic of Korea
- Language:English
- Abstract: In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.
